Top Markets
Coin of the day
Nordicus Partners Corporation Nordicus Partners Corporation

Nordicus Partners Corporation

NORD
Classement en actions #23226
Nordicus Partners Corporation functions as a publicly traded entity that acts... Nordicus Partners Corporation functions as a publicly traded entity that acts as both a business accelerator and a holding company, specifically supporting Nordic life sciences firms operating within the United States. A central focus for the company involves advancing oral healthcare through the development of new medicines. In addition to its core operations, Nordicus offers an array of corporate finance and advisory services. These include aiding in business and market expansion, formulating strategic growth plans, identifying and acquiring talent, fostering key partnerships, facilitating capital raising efforts, and orchestrating company acquisitions or sales. The organization, which was established in 1993 and is headquartered in Beverly Hills, California, rebranded as Nordicus Partners Corporation in May 2023, having previously been known as EKIMAS Corporation.
Prix de l'action
$4.06
Dernière synchronisation: 2026-08-21
Capitalisation boursière
$76.69M
Changement (1 jour)
-0.98%
Changement (1 an)
125.56%
Pays
US
Échange Nordicus Partners Corporation (NORD)

Catégorie

Bénéfices pour Nordicus Partners Corporation (NORD)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Nordicus Partners Corporation, les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Nordicus Partners Corporation de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
$867.49M -
CH
$940.90M -
US
$940.98M -
FR
$1.03B -
US
$897.00M -
US